Bicycle Therapeutics (NASDAQ:BCYC) Posts Earnings Results, Beats Expectations By $0.25 EPS

Key Points

• Bicycle Therapeutics beat quarterly expectations: The company reported a loss of $0.15 per share, $0.25 better than analysts’ expected loss of $0.40, while revenue of $34.06 million exceeded the $12.22 million consensus estimate.
• Shares remain under pressure: BCYC traded down to $3.67, near its 52-week low of $3.33, with a market capitalization of approximately $256.5 million.
• Analyst sentiment is mixed: The stock carries an average “Hold” rating and a consensus price target of $13.57, despite a recent Jefferies “Buy” rating with a $10 target and several bearish recommendations.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.25, FiscalAI reports. The company had revenue of $34.06 million during the quarter, compared to analysts' expectations of $12.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%.

Bicycle Therapeutics Price Performance

Shares of BCYC stock traded down $0.15 during trading hours on Friday, hitting $3.67. 231,733 shares of the company's stock were exchanged, compared to its average volume of 423,246. The stock has a market cap of $256.52 million, a price-to-earnings ratio of -1.34 and a beta of 1.68. The stock's 50-day moving average is $3.85 and its 200-day moving average is $4.60. Bicycle Therapeutics has a 52 week low of $3.33 and a 52 week high of $8.48.

Analyst Upgrades and Downgrades

BCYC has been the topic of several research reports. Jefferies Financial Group reissued a "buy" rating and set a $10.00 price target on shares of Bicycle Therapeutics in a research report on Thursday. Weiss Ratings reissued a "sell (e+)" rating on shares of Bicycle Therapeutics in a research note on Friday, October 2nd. Zacks Research downgraded Bicycle Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, October 14th. Needham & Company LLC decreased their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Finally, Wall Street Zen upgraded Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $13.57.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics' research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.